Ajouter aux favoris   Ajouter cette page à mon bookmark --- SOCIAL BOOKMARKING --- Digg Furl del.icio.us Netscape

Introduction
Recognizing that prolonging disease-free survival in chronic leukemia relies on the eradication of minimal residual disease has raised the bar for developers of novel pharmacotherapy. In meeting the more demanding success criteria and targeting innovative treatments to cohorts most likely to respond, developers should increasingly employ the use of molecular markers to guide risk stratification.

Scope
Overview of chronic leukemias including epidemiology, etiology, clinical features, staging and prognostic variables
Current treatment controversies and novel therapies in the developmental pipeline
Analysis of trial data, marketing factors and commercial potential for key technologies in clinical development
Stakeholder opinions and interview transcripts based on qualitative interviews with five opinion leaders from the US and Europe
Highlights
Because of the heterogeneity of CLL there is a need to identify biological markers that provide a more robust and reliable prediction of patient outcomes to current and evolving treatment strategies. The identification and application of molecular markers to facilitate prognostication is becoming integral to the treatment decision-making process.

The emergence of Gleevec-resistant CML, reported at rates of 4% with each year of treatment, coupled with only a 50% response rate in patients with advanced disease, indicate the need for novel, efficacious second-line treatment strategies both for patients with Gleevec-resistant chronic phase CML and for virtually all advanced stage patients.

The goal for developers of novel CLL pharmacotherapy is to innovate drug treatments that can salvage patients refractory to alemtuzumab and improve on the former's toxicity while simultaneously increasing the rate and duration of minimal residual disease negativity.

Reasons to Purchase
Identify opportunities for more efficacious second-line treatment strategies both for patients with Gleevec-resistant CML and advanced stage patients
Understand how future advancements in chronic leukemia prognostication have the potential to shift treatment paradigms
Assess opportunities and challenges facing innovative treatments for chronic leukemias, in particular the drive to eradicate minimal residual disease

Introduction
Recognizing that prolonging disease-free survival in chronic leukemia relies on the eradication of minimal residual disease has raised the bar for developers of novel pharmacotherapy. In meeting the more demanding success criteria and targeting innovative treatments to cohorts most likely to respond, developers should increasingly employ the use of molecular markers to guide risk stratification.

Scope
Overview of chronic leukemias including epidemiology, etiology, clinical features, staging and prognostic variables
Current treatment controversies and novel therapies in the developmental pipeline
Analysis of trial data, marketing factors and commercial potential for key technologies in clinical development
Stakeholder opinions and interview transcripts based on qualitative interviews with five opinion leaders from the US and Europe
Highlights
Because of the heterogeneity of CLL there is a need to identify biological markers that provide a more robust and reliable prediction of patient outcomes to current and evolving treatment strategies. The identification and application of molecular markers to facilitate prognostication is becoming integral to the treatment decision-making process.

The emergence of Gleevec-resistant CML, reported at rates of 4% with each year of treatment, coupled with only a 50% response rate in patients with advanced disease, indicate the need for novel, efficacious second-line treatment strategies both for patients with Gleevec-resistant chronic phase CML and for virtually all advanced stage patients.

The goal for developers of novel CLL pharmacotherapy is to innovate drug treatments that can salvage patients refractory to alemtuzumab and improve on the former's toxicity while simultaneously increasing the rate and duration of minimal residual disease negativity.

Reasons to Purchase
Identify opportunities for more efficacious second-line treatment strategies both for patients with Gleevec-resistant CML and advanced stage patients
Understand how future advancements in chronic leukemia prognostication have the potential to shift treatment paradigms
Assess opportunities and challenges facing innovative treatments for chronic leukemias, in particular the drive to eradicate minimal residual disease